A preliminary evaluation to review the scope and quality of evidence surrounding transdermal buprenorphine use in the pediatric setting for non-surgical pain was conducted. Our review revealed limited data available on the use of transdermal buprenorphine in pediatric patients. Most studies surrounding this subject involve accidental ingestion of buprenorphine and its use in the treatment of neonatal abstinence syndrome. While indicated for use only in adult populations, small studies have shown encouraging results in reducing pain in children with few, if any, adverse effects. This is reassuring from a clinical perspective, as we hope to highlight the available evidence and invite researchers to expand future studies. Through this review, we have identified significant gaps in the literature surrounding the safety and use of buprenorphine in the pediatric population. To our knowledge, there are no major studies investigating this subject, and it is our hope that future studies will explore the use of transdermal buprenorphine as an alternative pain management technique in pediatrics. The intent of our scoping review is to highlight the lack of research in this area; therefore, future studies may be conducted to support its use in North America.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874292PMC
http://dx.doi.org/10.7759/cureus.5954DOI Listing

Publication Analysis

Top Keywords

transdermal buprenorphine
16
buprenorphine pediatric
12
future studies
12
scoping review
8
non-surgical pain
8
pediatric population
8
buprenorphine
6
studies
6
transdermal
4
review transdermal
4

Similar Publications

Background: Transdermal buprenorphine is used for the management of postoperative pain. Its effectiveness for the postoperative pain management following mandibular resection and reconstruction has yet to be evaluated.

Purpose: To evaluate the efficacy of transdermal buprenorphine patch (TBP) in managing postoperative pain after mandibular resection and reconstruction with anterior iliac crest graft.

View Article and Find Full Text PDF

Impact of transdermal buprenorphine patch combined with celecoxib on improving shoulder pain and function of patients with primary adhesive shoulder capsulitis.

BMC Musculoskelet Disord

November 2024

Department of Pain, The Third People's Hospital of Hubei Province, Jianghan University, No. 26 Zhongshan Avenue, Wuhan, Hubei, 430022, China.

Background: One of the main purposes of clinical treatment for adhesive shoulder capsulitis is pain relief. However, patients often fail to achieve a satisfactory therapeutic response. This study aims to evaluate the impact of a combination therapy involving buprenorphine transdermal patch and celecoxib capsules on improving shoulder pain and function of patients with primary adhesive shoulder capsulitis (ASC).

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness of buprenorphine (BTP) and ketoprofen (KTP) transdermal patches for managing post-operative pain specifically after total knee replacement surgeries, using 100 patients divided into two treatment groups.
  • Results show that the BTP group experienced significantly lower pain scores at rest on days 2 to 5 post-surgery, indicating better pain management, while the KTP group required more rescue pain relief.
  • Overall, buprenorphine patches appear to provide superior pain relief and higher patient satisfaction without significant side effects compared to ketoprofen in the early post-operative period.
View Article and Find Full Text PDF

24-Hour Induction of Transdermal Buprenorphine to Buprenorphine Extended-Release.

J Psychoactive Drugs

November 2024

Pharmacokinetics Modeling and Simulation Laboratory, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.

Buprenorphine is an effective treatment for opioid use disorder but can be slow when using a standard low-dose titration protocol to avoid precipitated withdrawal. This presents a substantial practical barrier in clinical practice. Recent low-dose induction strategies have attempted to simplify and shorten the process required for successful induction, including our own transdermal buprenorphine method, which achieves induction to sublingual buprenorphine/naloxone after 48 h.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!